

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Amplia Therapeutics Limited
ABN	16 165 160 841

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Warwick Bonner Tong
Date of last notice	5 August 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
Date of change	17 September 2019
No. of securities held prior to change	1,741,428 Fully Paid Ordinary Shares 40,000 Options Exercise Price A\$0.15 Expiry Date 30 June 2022
Class	Fully Paid Ordinary Shares Options Exercise Price A\$0.15 Expiry Date 30 June 2022
Number acquired	250,000 Shares 125,000 Options
Number disposed	Nil

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$0.10 per share Free Options attaching on basis of 1 Option for every 2 shares
No. of securities held after change	1,741,428 Fully Paid Ordinary Shares 250,000 Fully Paid Ordinary Shares 40,000 Options Exercise Price A\$0.15 Expiry Date 30 June 2022 125,000 Options Exercise Price A\$0.15 Expiry Date 30 June 2022
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Placement approved by shareholders at Annual General Meeting held on 30 August 2019.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

17 September 2019

+ See chapter 19 for defined terms.